Regenerative Medicine Market in the US 2016-2020

アメリカの再生医療市場2016-2020

◆タイトル:Regenerative Medicine Market in the US 2016-2020
◆商品コード:IRTNTR7731
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2015年12月23日
◆ページ数:77
◆資料形式:pdf / 英語
◆納品方法:Eメール
◆調査対象地域:北米
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥277,500見積依頼/購入/質問フォーム
Five UserUSD3,000 ⇒換算¥333,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥444,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、アメリカの再生医療市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、アメリカの再生医療市場規模及び予測、用途別分析、製品別分析、市場の成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。

Regenerative medicine deals with the process of using therapeutically-induced or laboratory grown human tissue to treat diseased or injured human cells, tissues, or organs. It is an emerging field of treatment that helps in producing new cells to substitute malfunctioning or injured cells as a vehicle to treat disease and injury. The regenerative medicine market can be characterized into three major modalities, namely tissue engineering, biomaterials/biomolecules, and stem cell therapy.

Technavio market research analysts expect the regenerative medicine market in the US to grow at a fast pace, posting a remarkable CAGR of more than 33% during the forecast period because of the growing demand for tissue-engineered and stem cell products for the treatment of various diseases. The potential of these medicines in regenerating diseased organs is one of the major factors that drives the market in the US. The stem cells application and advancements in nanotechnology will further drive the progress in this market.

Cell therapy helps in treating the diseases or to improving the functioning of the existing cells, by administrating of cells into the body. This therapy addresses medical conditions related to the bone, cartilage, heart, skin, digestive system, reproductive system, eye, blood, spine, brain, and the nervous system. In 2015, cell therapy segment accounted for approximately 80% of the market share.

The report offers an analysis of each of the following segments and discusses its impact on the overall market growth -
- Cell therapy
- Scaffold

The year 2015 saw the precedence of the dermatology segment, accounting for a market share of more than 51%. Dermatology includes the treatment of burns and chronic wounds that requires a quick response, and skin grafting is essential in many cases. Factors such as the increase in obesity and diabetes, growing elderly population, and an increase in life expectancy are some of the causes contributing to the growth of the dermatology market.

The report offers an analysis of each of the following segments and discusses its impact on the overall market growth -
Dermatology
Musculoskeletal
Ocular
Cardiovascular

【資料の目次】

Table of Contents
PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Top vendor offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights

PART 05: Gene therapy: An emerging field in regenerative medicine

PART 06: Pipeline portfolio

PART 07: Regulatory scenario
• FDA process

PART 08: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis

PART 09: Market segmentation by product
• Cell therapy
• Cell therapy market in US
• Scaffold
• Scaffold market in US

PART 10: Market segmentation by application
• Dermatology
• Musculoskeletal
• Ocular
• Cardiovascular

PART 11: Market drivers
• Rise in prevalence of chronic diseases
• Technological innovations
• Increase in investment for research and development activities

PART 12: Impact of drivers

PART 13: Market challenges
• Stringent regulatory approval process
• Ethical challenges
• Lack of clinical data

PART 14: Impact of drivers and challenges

PART 15: Market trends
• Increase in pipeline products
• Strategic alliances
• Potential of regenerative medicine toward decreasing healthcare costs

PART 16: Vendor landscape
• Competitive scenario
• Key news
• Mergers and acquisitions
• Key vendor analysis 2015
• Other prominent vendors

PART 17: Key vendor analysis
• Acelity
• Mesoblast
• Organogenesis
• Reprocell
• Stryker

PART 18: Appendix
• List of abbreviations

PART 19: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Number of ongoing clinical trials
Exhibit 03: Gene therapy pipeline products based on indication
Exhibit 04: Gene therapy research by sponsorship
Exhibit 05: Some of the pipeline products of gene therapy
Exhibit 06: Pipeline products of regenerative medicine for cardiovascular diseases
Exhibit 07: Pipeline products of regenerative medicine for central nervous system diseases
Exhibit 08: Pipeline products of regenerative medicine for spine and orthopedics diseases
Exhibit 09: Pipeline products of regenerative medicine for diabetes and autoimmune diseases
Exhibit 10: Overview of number of companies and products of regenerative medicine
Exhibit 11: Financial performance of regenerative medicine 2013 and 2014
Exhibit 12: Marketed products of different therapy areas in 2014
Exhibit 13: Regenerative medicine stakeholders
Exhibit 14: Guidelines to be followed prior to the initiation of clinical studies for regenerative products
Exhibit 15: Regenerative medicine market in US 2015-2020 ($ millions)
Exhibit 16: Five forces analysis
Exhibit 17: Cell therapy procedure
Exhibit 18: Cell therapy market in US 2015-2020 ($ millions)
Exhibit 19: Scaffold market in US 2015-2020 ($ millions)
Exhibit 20: Segmentation of regenerative medicine market in US 2015-2020 ($ millions)
Exhibit 21: Segmentation of regenerative medicine market in US 2015-2020
Exhibit 22: Segmentation of regenerative medicine by application 2015
Exhibit 23: Revenues funded by federal agencies for regenerative medicine research
Exhibit 24: Impact of drivers
Exhibit 25: Impact of drivers and challenges
Exhibit 26: Some of the mid- and late-stage pipeline products for regenerative medicine
Exhibit 27: Mesoblast: Key takeaways
Exhibit 28: Reprocell: Key takeaways
Exhibit 29: Acelity: Key takeaways
Exhibit 30: Organogenesis: Key takeaways
Exhibit 31: Stryker: Key takeaways
Exhibit 32: Acelity: Business segmentation by revenue 2014
Exhibit 33: Acelity: Business segmentation by revenue 2013 and 2014
Exhibit 34: Acelity: Geographical segmentation by revenue 2014
Exhibit 35: Mesoblast: Product pipeline
Exhibit 36: Organogenesis: Product offerings
Exhibit 37: Reprocell: Product categories
Exhibit 38: Stryker: Business/product segmentation by revenue 2014
Exhibit 39: Stryker: Business segmentation by revenue 2013 and 2014 ($ millions)



【掲載企業】

Acelity, Mesoblast, Organogenesis, Reprocell, Stryker, Aastrom Biosciences, Acologix, AlloCure, Allosource, Alphatec Spine, Altrika, Amorcyte, Argos Therapeutics, Athersys, Avita Medical, Axogen, Bacterin International, Baxter, Bellicum Pharmaceuticals, BioCardia, BioLife Solutions, BioRestorative Therapies, BioTissue Technologies, Bluebird Bio, BrainStorm Cell Therapeutics, Calimmune, Capricor, Celyad (Cardio3 BioSciences), Cell Medica, Cesca, CryoLife, Cynata Therapeutics, Cytori, Cytori Therapeutics, Dendreon, DiscGenics, Fate Therapeutics, Fibrocell, Fibrocell Science, Forticell Bioscience, Fortress Biotech, Gamida Cell, Geron, Harvard Apparatus Regenerative Technology, Healthpoint, Histogen, Histogenics, Humacyte, Immunocellular Therapeutics P, Integra Life Sciences, Intercytex, InVivo Therapeutics, iSTO Technologies, Juventas Therapeutics, Kensey Nash, Kiadis Pharma, Kinetic Concept, Living Cell Technologies, MaxCyte, Medtronics, Mesoblast, MiMedix Group, Nanofiber Solutions CTO, Nanotope, Neuralstem, Newlink Genetics, Northwest Biotherapeutics, NovaRx, Ocata Therapeutics, Opexa , Therapeutics, Organovo Holdings, Orteq, Orthofix, Osiris Therapeutics, Osteotech, Pfizer, Pluristem Therapeutics, Prima BioMed, Q Therapeutics, RhinoCyte, RTI Surgical, SanBio, Sangamo, Shire Regenerative Medicine, StemCells, Stratatech, TEI Biosciences, Tengion, Thermo Fischer Scientific, TiGenix, Tissue Genesis, TissueGene, VentriNova, Vericel, ViaCyte, Vistagen, and Zimmer.

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[アメリカの再生医療市場2016-2020] (Regenerative Medicine Market in the US 2016-2020 / IRTNTR7731)販売に関する免責事項
[アメリカの再生医療市場2016-2020] (Regenerative Medicine Market in the US 2016-2020 / IRTNTR7731)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆